Personalised medicine markers of anti-EGFR antibody therapy in metastatic colorectal cancer: accelerating clinical translation with collaborative meta-analyses based on individual-participant data

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1085364

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

When selecting cancer therapy we take into account ‘biomarkers’, biological cancer characteristics that predict treatment success. We will work with an international group, the Advanced Colorectal Cancer Database, to analyse individual patient clinical trial data. We intend to validate biomarkers used to select treatment with cetuximab or panitumumab. Cancer genes called KRAS, NRAS, PTEN, PIK3CA, EREG and BRAF will be examined. Our study will provide best evidence for personalised treatment.

Funded Activity Details

Start Date: 01-01-2015

End Date: 01-01-2018

Funding Scheme: Project Grants

Funding Amount: $300,953.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Cancer Therapy (excl. Chemotherapy and Radiation Therapy)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

biomarkers | cancer research | colon cancer | diagnostic marker | targeted therapy

Related Links